Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Guardado en:
Detalles Bibliográficos
Autores principales: Jacob E Choby, Tugba Ozturk, Sarah W Satola, Jesse T Jacob, David S Weiss
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Medicine (General)
R5-920
Microbiology
QR1-502
Acceso en línea:https://doaj.org/article/4f90525ab70e4605bd217ae9a096e2fe
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4f90525ab70e4605bd217ae9a096e2fe
record_format dspace
spelling oai:doaj.org-article:4f90525ab70e4605bd217ae9a096e2fe2021-12-02T05:03:52ZDoes cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?2666-524710.1016/S2666-5247(21)00271-8https://doaj.org/article/4f90525ab70e4605bd217ae9a096e2fe2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666524721002718https://doaj.org/toc/2666-5247Jacob E ChobyTugba OzturkSarah W SatolaJesse T JacobDavid S WeissElsevierarticleMedicine (General)R5-920MicrobiologyQR1-502ENThe Lancet Microbe, Vol 2, Iss 12, Pp e648-e649 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
Microbiology
QR1-502
spellingShingle Medicine (General)
R5-920
Microbiology
QR1-502
Jacob E Choby
Tugba Ozturk
Sarah W Satola
Jesse T Jacob
David S Weiss
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
format article
author Jacob E Choby
Tugba Ozturk
Sarah W Satola
Jesse T Jacob
David S Weiss
author_facet Jacob E Choby
Tugba Ozturk
Sarah W Satola
Jesse T Jacob
David S Weiss
author_sort Jacob E Choby
title Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
title_short Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
title_full Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
title_fullStr Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
title_full_unstemmed Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
title_sort does cefiderocol heteroresistance explain the discrepancy between the apeks-np and credible-cr clinical trial results?
publisher Elsevier
publishDate 2021
url https://doaj.org/article/4f90525ab70e4605bd217ae9a096e2fe
work_keys_str_mv AT jacobechoby doescefiderocolheteroresistanceexplainthediscrepancybetweentheapeksnpandcrediblecrclinicaltrialresults
AT tugbaozturk doescefiderocolheteroresistanceexplainthediscrepancybetweentheapeksnpandcrediblecrclinicaltrialresults
AT sarahwsatola doescefiderocolheteroresistanceexplainthediscrepancybetweentheapeksnpandcrediblecrclinicaltrialresults
AT jessetjacob doescefiderocolheteroresistanceexplainthediscrepancybetweentheapeksnpandcrediblecrclinicaltrialresults
AT davidsweiss doescefiderocolheteroresistanceexplainthediscrepancybetweentheapeksnpandcrediblecrclinicaltrialresults
_version_ 1718400648987279360

Ejemplares similares